Singapore, 6 November 2013 – Menarini Asia-Pacific, a member of the world's largest Italian biopharmaceutical company, officially inaugurated the establishment of Menarini (China) Investment Co. Ltd. and the opening of its national headquarters on 29 October 2013 at the Wuhan National Bioindustry Base ("Wuhan Biolake") in Hubei Province, China.
Menarini Asia-Pacific operates in the fastest growing healthcare markets worldwide, growing at an compounded annual growth rate of 6.0 percent over the past 4 years, approximately 2.6 times the global pharmaceutical market growth. Today, the total Asia-Pacific Pharmaceutical markets represent approximately USD 232 billion* and 18.4 percent* of worldwide pharmaceutical sales.
Menarini Asia-Pacific has instituted proprietary Marketing and Sales processes to launch and optimize brands across the region. The rigorous, data-driven approach to Marketing leverages on proven analytical tools to make the right strategic choices. The unique Sales model is tightly integrated with Marketing and is customized for the Asia-Pacific markets.
Menarini Asia-Pacific also utilizes a proprietary Launch Playbook to ensure full cross-functional readiness well in advance of a product launch in areas such as regulatory status optimization, physician advocacy development, PR, medical publication planning, consumer activation, trade marketing, and supply chain / channel strategy.
Menarini Asia-Pacific has successfully submitted over 200 New Chemical Entities (NCEs) since 2006 and holds over 1,000 licenses. With over 50 experienced Regulatory professionals across the region and an ever expanding network of Key Opinion Leaders, these have enabled an efficacious pre-marketing execution. Menarini Asia-Pacific's Medical, Clinical Operation and Pharmacovigilance capabilities are well-established, able to deliver high quality medical support, ICH** GCP*** compliant clinical studies and round the clock safety surveillance in accordance with EU guidelines.
Menarini Asia-Pacific operates effectively across a broad range of therapeutic areas:
*Source: IQVIA 1Q2018; BMI July 2018
**International Conference on Harmonisation
***Good Clinical Practice